Scholarlink

<p>We report a case of fulminant invasive meningococcal disease caused by <i>Neisseria meningitidis</i> serogroup Y in a young, immunocompromised adult with myasthenia gravis receiving long-term immunosuppressive therapy including ravulizumab, despite prior meningococcal vaccination. Serogroup Y is increasingly recognized in epidemiological surveillance and may be associated with atypical clinical manifestations, including the uncommon coexistence of meningitis and pulmonary involvement, as observed in this patient. The illness was characterized by rapid progression to septic shock, meningitis, and presumed pleuropneumonia. Diagnosis was confirmed by both blood PCR and culture. This case highlights the increased susceptibility to invasive meningococcal infections in individuals receiving complement-inhibiting therapy and underscores the importance of comprehensive preventive strategies, including a carefully planned and implemented vaccination schedule and careful individualized consideration of antimicrobial prophylaxis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Breakthrough serogroup Y meningococcal disease in a vaccinated patient with myasthenia gravis receiving ravulizumab: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月20日

查看全文
  • Silvija Šoprek Strugar,
  • Paško Petrović,
  • Iva Butić,
  • Branimir Gjurašin,
  • Marko Kutleša

摘要

We report a case of fulminant invasive meningococcal disease caused by Neisseria meningitidis serogroup Y in a young, immunocompromised adult with myasthenia gravis receiving long-term immunosuppressive therapy including ravulizumab, despite prior meningococcal vaccination. Serogroup Y is increasingly recognized in epidemiological surveillance and may be associated with atypical clinical manifestations, including the uncommon coexistence of meningitis and pulmonary involvement, as observed in this patient. The illness was characterized by rapid progression to septic shock, meningitis, and presumed pleuropneumonia. Diagnosis was confirmed by both blood PCR and culture. This case highlights the increased susceptibility to invasive meningococcal infections in individuals receiving complement-inhibiting therapy and underscores the importance of comprehensive preventive strategies, including a carefully planned and implemented vaccination schedule and careful individualized consideration of antimicrobial prophylaxis.